Literature DB >> 22090068

Validation of the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND).

Allan M Glanzman1, Michael P McDermott, Jacqueline Montes, William B Martens, Jean Flickinger, Susan Riley, Janet Quigley, Sally Dunaway, Jessica O'Hagen, Liyong Deng, Wendy K Chung, Rabi Tawil, Basil T Darras, Michele Yang, Douglas Sproule, Darryl C De Vivo, Petra Kaufmann, Richard S Finkel.   

Abstract

PURPOSE: Preliminary validation of the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) for motor skill assessment in spinal muscular atrophy type I.
METHODS: A total of 27 subjects 3 to 260 months old (mean = 49, SD = 69) with spinal muscular atrophy-I were evaluated with the CHOP INTEND. Subjects were evaluated as part of a multicenter natural history study.
RESULTS: CHOP INTEND scores and age were significantly correlated (r = -0.51, P = .007; 2 survival of the motor neuron [SMN] 2 gene copies, n = 16, r = -0.60, 3 SMN2 gene copies, n = 9, r = -0.83). Respiratory support and CHOP INTEND scores were correlated (r = -0.74, P < .0001, n = 26). The CHOP INTEND and age regression in patients with 2 copies versus 3 copies of SMN2 approached significance (P = .0711, n = 25). Subjects who required respiratory support scored significantly lower (mean = 15.5, SD = 10.2 vs mean = 31.2, SD = 4.2, P < .0001, n = 27). Correlation with motor unit number estimation and combined motor unit activation were not significant.
CONCLUSION: The CHOP INTEND reflects measures of disease severity and supports continued exploration of the CHOP INTEND.

Entities:  

Mesh:

Year:  2011        PMID: 22090068     DOI: 10.1097/PEP.0b013e3182351f04

Source DB:  PubMed          Journal:  Pediatr Phys Ther        ISSN: 0898-5669            Impact factor:   3.049


  23 in total

1.  Rasch analysis of clinical outcome measures in spinal muscular atrophy.

Authors:  Stefan J Cano; Anna Mayhew; Allan M Glanzman; Kristin J Krosschell; Kathryn J Swoboda; Marion Main; Birgit F Steffensen; Carole Bérard; Françoise Girardot; Christine A M Payan; Eugenio Mercuri; Elena Mazzone; Bakri Elsheikh; Julaine Florence; Linda S Hynan; Susan T Iannaccone; Leslie L Nelson; Shree Pandya; Michael Rose; Charles Scott; Reza Sadjadi; Mackensie A Yore; Cynthia Joyce; John T Kissel
Journal:  Muscle Nerve       Date:  2013-07-26       Impact factor: 3.217

Review 2.  Spinal muscular atrophy: state of the art and new therapeutic strategies.

Authors:  Sonia Messina; Maria Sframeli; Lorenzo Maggi; Adele D'Amico; Claudio Bruno; Giacomo Comi; Eugenio Mercuri
Journal:  Neurol Sci       Date:  2021-04-19       Impact factor: 3.307

3.  Spectrum of neuropathophysiology in spinal muscular atrophy type I.

Authors:  Brian N Harding; Shingo Kariya; Umrao R Monani; Wendy K Chung; Maryjane Benton; Sabrina W Yum; Gihan Tennekoon; Richard S Finkel
Journal:  J Neuropathol Exp Neurol       Date:  2015-01       Impact factor: 3.685

4.  Nusinersen Treatment in Adults With Spinal Muscular Atrophy.

Authors:  Tina Duong; Connie Wolford; Michael P McDermott; Chelsea E Macpherson; Amy Pasternak; Allan M Glanzman; William B Martens; Elizabeth Kichula; Basil T Darras; Darryl C De Vivo; Zarazuela Zolkipli-Cunningham; Richard S Finkel; Michael Zeineh; Max Wintermark; Jacinda Sampson; Katharine A Hagerman; Sally Dunaway Young; John W Day
Journal:  Neurol Clin Pract       Date:  2021-06

Review 5.  Spinal muscular atrophy.

Authors:  Eugenio Mercuri; Charlotte J Sumner; Francesco Muntoni; Basil T Darras; Richard S Finkel
Journal:  Nat Rev Dis Primers       Date:  2022-08-04       Impact factor: 65.038

6.  Translation and cross-cultural adaptation of the Charcot-Marie-Tooth disease Pediatric Scale to Brazilian Portuguese and determination of its measurement properties.

Authors:  Karoliny Lisandra Teixeira Cruz; Ana Cristina Resende Camargos; Juliana Cardoso; Cyntia Rogean de Jesus Alves de Baptista; Aline Duprat Ramos; Ana Claudia Mattiello-Sverzut; Joshua Burns; Hércules Ribeiro Leite
Journal:  Braz J Phys Ther       Date:  2020-08-07       Impact factor: 3.377

7.  An observational study of functional abilities in infants, children, and adults with type 1 SMA.

Authors:  Marika Pane; Concetta Palermo; Sonia Messina; Valeria A Sansone; Claudio Bruno; Michela Catteruccia; Maria Sframeli; Emilio Albamonte; Marina Pedemonte; Adele D'Amico; Giorgia Brigati; Roberto de Sanctis; Giorgia Coratti; Simona Lucibello; Enrico Bertini; Giuseppe Vita; Francesco Danilo Tiziano; Eugenio Mercuri
Journal:  Neurology       Date:  2018-07-25       Impact factor: 9.910

8.  Motor Function Test Reliability During the NeuroNEXT Spinal Muscular Atrophy Infant Biomarker Study.

Authors:  Kristin J Krosschell; Michael Bosch; Leslie Nelson; Tina Duong; Linda P Lowes; Lindsay N Alfano; Danielle Benjamin; Terri B Carry; Ginger Devine; Carolyn Kelley; Rebecca Gadekan; Elizabeth C Malkus; Amy Pasternak; Stephanie Provance-Orr; Lynne Roemeiser-Logan; Alina Nicorici; Donata Trussell; Sally Dunaway Young; Jennifer R Fetterman; Jacqueline Montes; Penny J Powers; Rebecca Quinones; Janet Quigley; Christopher S Coffey; Jon W Yankey; Amy Bartlett; John T Kissel; Stephen J Kolb
Journal:  J Neuromuscul Dis       Date:  2018

9.  Oral and Swallowing Abilities Tool (OrSAT) for Type 1 SMA Patients: Development of a New Module.

Authors:  Beatrice Berti; Lavinia Fanelli; Roberto de Sanctis; Roberta Onesimo; Concetta Palermo; Daniela Leone; Sara Carnicella; Giulia Norcia; Nicola Forcina; Giorgia Coratti; Valentina Giorgio; Antonella Cerchiari; Simona Lucibello; Richard Finkel; Marika Pane; Eugenio Mercuri
Journal:  J Neuromuscul Dis       Date:  2021

10.  International Workshop:: Outcome measures and clinical trial readiness in primary mitochondrial myopathies in children and adults. Consensus recommendations. 16-18 November 2016, Rome, Italy.

Authors:  Michelangelo Mancuso; Robert McFarland; Thomas Klopstock; Michio Hirano
Journal:  Neuromuscul Disord       Date:  2017-09-08       Impact factor: 4.296

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.